Lisbeth Skoge
Papers
1
Total Citations
30
H-Index
1
About
Lisbeth Skoge is a pioneering translational researcher in cancer immunotherapy, with a primary focus on developing personalized dendritic cell (DC) vaccines for high-risk prostate cancer. Her landmark work includes leading a long-term, first-in-man Phase I/II study that investigated an adjuvant DC vaccine administered after radical prostatectomy. This study, which has garnered 30 citations, demonstrated the feasibility and safety of a personalized approach to reduce the risk of biochemical relapse—a critical step toward preventing noncurative disease progression in patients with aggressive prostate cancer. Skoge’s contributions lie at the intersection of immunology and oncology, where she has advanced the clinical application of autologous dendritic cells as a therapeutic strategy. Her research not only highlights the potential of tailored vaccines to improve outcomes in high-risk populations but also establishes a foundation for future combination immunotherapies. Through her rigorous clinical trials, Skoge has helped bridge the gap between bench and bedside, offering new hope for patients facing limited treatment options after surgery. Her work continues to influence the design of next-generation cancer vaccines.
Research Focus
Key Achievements
Top Papers
- 1